31 – 40 of 608
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH) : a randomised, open-label, phase 2/3 superiority trial
(2025) In The Lancet
- Contribution to journal › Article
-
Mark
Janus kinase 1 inhibitors for treating immune checkpoint inhibitor-induced enterocolitis - report of two filgotinib-treated cases and literature review
- Contribution to journal › Scientific review
-
Mark
Temporal trends in relative survival of diffuse large B-cell lymphoma in Sweden and Denmark in the era of targeted and cellular therapies
- Contribution to journal › Letter
-
Mark
Inter-reader agreement of quantitative FDG PET/CT biomarkers in lymphoma : a multicentre evaluation of MTV, TLG and Dmax
- Contribution to journal › Article
- 2024
-
Mark
Ovanligt symtom med hög klinisk valör vid Hodgkins lymfom
- Contribution to journal › Article
-
Mark
Infections in patients with mantle cell lymphoma
- Contribution to journal › Article
-
Mark
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial
- Contribution to journal › Article
-
Mark
Body mass index and risk of over 100 cancer forms and subtypes in 4.1 million individuals in Sweden : the Obesity and Disease Development Sweden (ODDS) pooled cohort study
- Contribution to journal › Article
-
Mark
Translation and ligusistic Validation of the Multidimensional Dyspnea Profile into Hindi in a Palliative Care setting
- Contribution to journal › Article
-
Mark
Elderly long-term survivors in the Nordic phase II study with first-line maintenance temozolomide for primary central nervous system lymphoma : a 10-year follow-up
- Contribution to journal › Letter
